000285814 001__ 285814
000285814 005__ 20260401151453.0
000285814 0247_ $$2doi$$a10.59249/CTWM1697
000285814 0247_ $$2pmid$$apmid:41918512
000285814 0247_ $$2pmc$$apmc:PMC13023422
000285814 0247_ $$2ISSN$$a0044-0086
000285814 0247_ $$2ISSN$$a1551-4056
000285814 037__ $$aDZNE-2026-00350
000285814 041__ $$aEnglish
000285814 082__ $$a610
000285814 1001_ $$aAli, Mehak$$b0
000285814 245__ $$aChrysoeriol-Mediated Neuroprotection in Parkinson's Disease in Mice: Targeting Apoptosis, α-Synuclein Accumulation, and Functional Recovery.
000285814 260__ $$aNew Haven, Conn.$$b[Verlag nicht ermittelbar]$$c2026
000285814 3367_ $$2DRIVER$$aarticle
000285814 3367_ $$2DataCite$$aOutput Types/Journal article
000285814 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1775049203_19920
000285814 3367_ $$2BibTeX$$aARTICLE
000285814 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285814 3367_ $$00$$2EndNote$$aJournal Article
000285814 520__ $$aParkinson's disease (PD) is a neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to significant motor dysfunction. Current treatments stabilize dopamine levels but fail to address underlying neuronal apoptosis, highlighting the need for novel approaches. Although chrysoeriol, a 3'-O-methoxy flavone and luteolin derivative, is well-documented for its anti-cancer, anti-diabetic, antioxidant, and anti-inflammatory properties, its neuroprotective potential in PD, particularly in vivo, remains largely unexplored. This study fills a critical gap by being the first to systematically assess chrysoeriol's neuroprotective effects in a PD mouse model. We evaluated the effects of 5 mg/kg chrysoeriol administered intraperitoneally (IP) for 14 days in an acute 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model. Behavioral tests showed notable recovery, as chrysoeriol eliminated deficits in motor function, coordination, and balance, as assessed by the pole test, forced swim test, and tail suspension test. It also mitigated exploratory and locomotor deficits in the open field test, and the Y-maze test revealed improved spatial and learning memory. Hematoxylin and eosin staining indicated a significant reduction in neuronal damage across key brain regions. qPCR analysis showed reduced 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity, downregulation of α-synuclein, and an improved Bcl-2/Bax ratio. These findings suggest chrysoeriol may protect against MPP+-induced apoptosis in mice, potentially via the PI3K/Akt signaling pathway, and reduces mitochondrial damage by downregulating α-synuclein.
000285814 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285814 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285814 650_7 $$2Other$$aBAX
000285814 650_7 $$2Other$$aBcl-2
000285814 650_7 $$2Other$$aNeuroprotective
000285814 650_7 $$2Other$$aParkinson’s disease
000285814 650_7 $$2Other$$achrysoeriol
000285814 650_7 $$2Other$$aα-Synuclein
000285814 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000285814 650_7 $$2NLM Chemicals$$aNeuroprotective Agents
000285814 650_7 $$2NLM Chemicals$$aFlavones
000285814 650_2 $$2MeSH$$aAnimals
000285814 650_2 $$2MeSH$$aApoptosis: drug effects
000285814 650_2 $$2MeSH$$aalpha-Synuclein: metabolism
000285814 650_2 $$2MeSH$$aNeuroprotective Agents: pharmacology
000285814 650_2 $$2MeSH$$aNeuroprotective Agents: therapeutic use
000285814 650_2 $$2MeSH$$aMale
000285814 650_2 $$2MeSH$$aParkinson Disease: drug therapy
000285814 650_2 $$2MeSH$$aParkinson Disease: metabolism
000285814 650_2 $$2MeSH$$aMice
000285814 650_2 $$2MeSH$$aMice, Inbred C57BL
000285814 650_2 $$2MeSH$$aDisease Models, Animal
000285814 650_2 $$2MeSH$$aRecovery of Function: drug effects
000285814 650_2 $$2MeSH$$aFlavones: pharmacology
000285814 650_2 $$2MeSH$$aNeuroprotection: drug effects
000285814 650_2 $$2MeSH$$aDopaminergic Neurons: drug effects
000285814 650_2 $$2MeSH$$aDopaminergic Neurons: metabolism
000285814 7001_ $$aMehreen, Mehwish$$b1
000285814 7001_ $$aBatool, Saima$$b2
000285814 7001_ $$aKhan, Shahrukh$$b3
000285814 7001_ $$aNoor, Aneeqa$$b4
000285814 7001_ $$aMumtaz, Sara$$b5
000285814 7001_ $$0P:(DE-2719)9000358$$aZafar, Saima$$b6$$eLast author$$udzne
000285814 773__ $$0PERI:(DE-600)2063545-X$$a10.59249/CTWM1697$$gVol. 99, no. 1, p. 111 - 126$$n1$$p111 - 126$$tYale journal of biology and medicine$$v99$$x0044-0086$$y2026
000285814 8564_ $$uhttps://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf$$yRestricted
000285814 8564_ $$uhttps://pub.dzne.de/record/285814/files/DZNE-2026-00350.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285814 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000358$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285814 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285814 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bYALE J BIOL MED : 2022$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-12
000285814 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-02-19T11:40:40Z
000285814 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-02-19T11:40:40Z
000285814 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review, Double anonymous peer review$$d2024-02-19T11:40:40Z
000285814 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2024-02-19T11:40:40Z
000285814 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-12
000285814 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarker$$x0
000285814 980__ $$ajournal
000285814 980__ $$aEDITORS
000285814 980__ $$aVDBINPRINT
000285814 980__ $$aI:(DE-2719)1440011-1
000285814 980__ $$aUNRESTRICTED